Biomarker identification in relapsed/refractory non-germinal center B-cell-like diffuse large B-cell lymphoma treated with Zanubrutinib

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please visit beigene.com for more information.

I am a Healthcare Professional from:

Biomarker identification in relapsed/refractory non-germinal center B-cell-like diffuse large B-cell lymphoma treated with Zanubrutinib

Rating

Rate this resource

Biomarker identification in relapsed/refractory non-germinal center B-cell-like diffuse large B-cell lymphoma treated with Zanubrutinib

Rating

Rate this resource

Related resources

Recent developments